1. Home
  2. SKYE vs SANG Comparison

SKYE vs SANG Comparison

Compare SKYE & SANG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKYE
  • SANG
  • Stock Information
  • Founded
  • SKYE 2012
  • SANG 1984
  • Country
  • SKYE United States
  • SANG Canada
  • Employees
  • SKYE N/A
  • SANG N/A
  • Industry
  • SKYE Biotechnology: Pharmaceutical Preparations
  • SANG Computer Software: Programming Data Processing
  • Sector
  • SKYE Health Care
  • SANG Technology
  • Exchange
  • SKYE Nasdaq
  • SANG Nasdaq
  • Market Cap
  • SKYE 94.0M
  • SANG 235.6M
  • IPO Year
  • SKYE N/A
  • SANG 2021
  • Fundamental
  • Price
  • SKYE $2.73
  • SANG $7.01
  • Analyst Decision
  • SKYE Buy
  • SANG
  • Analyst Count
  • SKYE 6
  • SANG 0
  • Target Price
  • SKYE $18.67
  • SANG N/A
  • AVG Volume (30 Days)
  • SKYE 167.7K
  • SANG 7.6K
  • Earning Date
  • SKYE 02-09-2025
  • SANG 02-06-2025
  • Dividend Yield
  • SKYE N/A
  • SANG N/A
  • EPS Growth
  • SKYE N/A
  • SANG N/A
  • EPS
  • SKYE N/A
  • SANG N/A
  • Revenue
  • SKYE N/A
  • SANG $244,406,000.00
  • Revenue This Year
  • SKYE N/A
  • SANG $3.36
  • Revenue Next Year
  • SKYE N/A
  • SANG $7.39
  • P/E Ratio
  • SKYE N/A
  • SANG N/A
  • Revenue Growth
  • SKYE N/A
  • SANG N/A
  • 52 Week Low
  • SKYE $2.25
  • SANG $2.50
  • 52 Week High
  • SKYE $19.41
  • SANG $7.20
  • Technical
  • Relative Strength Index (RSI)
  • SKYE 37.40
  • SANG 57.08
  • Support Level
  • SKYE $2.31
  • SANG $6.89
  • Resistance Level
  • SKYE $3.04
  • SANG $7.15
  • Average True Range (ATR)
  • SKYE 0.30
  • SANG 0.20
  • MACD
  • SKYE 0.07
  • SANG -0.02
  • Stochastic Oscillator
  • SKYE 44.68
  • SANG 51.28

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About SANG Sangoma Technologies Corporation

Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic centers: USA and Other countries. Key revenue is generated from USA.

Share on Social Networks: